Voyager Therapeutics, Inc. (VYGR)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-21

Key Insights

Chief Financial Officer Nathan Jorgensen is departing effective May 8, 2026, to pursue a new opportunity with no disagreement with the company, indicating a planned transition rather than a forced departure.
Robin Swartz, currently Chief Operating Officer and Chief Business Officer, is being promoted to principal financial officer and treasurer, leveraging her extensive finance background including over 10 years in finance roles at Sanofi Genzyme and recent CFO experience at Voyager (April-July 2024).
Amy Quinlan, Vice President of Finance since January 2025, is being elevated to principal accounting officer, bringing relevant controller and financial accounting experience from prior roles at Vor Biopharma and Tetraphase Pharmaceuticals.
The succession plan demonstrates internal depth and continuity, as both replacements are already embedded in the organization with recent experience in their new roles, minimizing external search costs and operational disruption.

Current Report Filed: 2026-01-08

Key Insights

Voyager Therapeutics filed a Form 8-K disclosing that they plan to present a corporate investor presentation and distribute a letter to specified stockholders, which contain updates and summaries of their business.
The company is cautioning investors that the information in the presentation and letter should not be considered filed under the Securities Exchange Act and is not necessarily material.
The 8-K includes forward-looking statements about the company's expectations for achieving preclinical and clinical development milestones, expanding beyond gene therapy and antibodies, and generating funding from its existing licensing and collaboration agreements.

Insider Trading Filed: 2026-01-08

Key Insights

Gregory L. Shiferman, SVP and General Counsel of Voyager Therapeutics, Inc., has been granted a stock option to purchase 100,000 shares of the company's common stock at an exercise price of $4.02 per share.
The stock option vests over four years, with 1/4th of the shares vesting on the one-year anniversary of the grant date and the remaining shares vesting monthly thereafter.
This transaction suggests that Shiferman, a key insider, is being incentivized to continue his leadership and contribution to the company's long-term success.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.